National Health Investors, Inc.

As of August 27, 2025, National Health Investors, Inc. is considered very attractive due to its undervalued status reflected in a P/E ratio of 23, a competitive EV to EBITDA ratio of 12.07, a solid ROCE of 14.97%, and a high dividend yield of 461.57%, despite recent underperformance compared to the S&P 500.

As of June 17, 2025, National Health Investors, Inc. is in a bearish trend, supported by bearish signals from the weekly MACD and daily moving averages, while monthly indicators show a mixed view.

As of May 30, 2025, National Health Investors, Inc. is fairly valued with a P/E ratio of 23, a strong dividend yield of 461.57%, and a ROCE of 14.97%, despite a high PEG ratio of 4.40 indicating premium growth expectations and an 8.37% stock return that underperformed the S&P 500's 10.26%.

As of March 2022, the management team of National Health Investors, Inc. includes Independent Chairman Mr. W. Andrew Adams and Independent Directors Mr. James Jobe, Mr. Robert McCabe, and Mr. Robert Webb.

National Health Investors, Inc. is a self-managed REIT focused on financing senior housing and medical investments, with a market cap of approximately $3.3 billion. As of March 2025, it reported net sales of $90 million and a net profit of $34 million.

As of Jun 18, National Health Investors, Inc. has a market capitalization of $3.30 billion, with net sales of $345.86 million and a net profit of $139.80 million over the last four quarters.